McKesson Corporation (NYSE:MCK) is among the 14 Best Pharma Dividend Stocks to Buy in 2025. In its Q4 2025 earnings announcement, the company plans to spin off its Medical-Surgical Solutions segment into a separate entity, “NewCo,” to enhance strategic direction. McKesson’s fiscal 2025 cash position was strong, with $3.5 billion returned to shareholders through buybacks and dividends. The company has increased dividends for eight years, with a 0.40% yield. While MCK shows investment potential, some AI stocks may offer greater upside. For more insights, check out the best short-term AI stock report.

Read more at Yahoo Finance: Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025?